Dr. Thigpen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2500 North State Street
Department Of Medicine/Division Of Oncology
Jackson, MS 39216Phone+1 601-366-9341
Education & Training
- University of Mississippi Medical CenterResidency, Internal Medicine, 1970 - 1973
- University of Mississippi Medical CenterFellowship, Hematology and Medical Oncology, 1968 - 1971
- University of RochesterInternship, Internal Medicine, 1969 - 1970
- University of Mississippi School of MedicineClass of 1969
Certifications & Licensure
- MS State Medical License 1969 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20
- Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
- Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Start of enrollment: 2008 Feb 25
- Join now to see all
Publications & Presentations
PubMed
- 372 citationsBevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncolog...Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson, Helen Huang, Lois M. Ramondetta
Lancet. 2017-10-07 - 102 citationsA preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.Charles F. Streckfus, Lenora Bigler, Michelle Tucci, James Tate Thigpen
Cancer Investigation. 2000-01-01 - 17 citationsEvaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.Lenora Bigler, J. Tate Thigpen, John A. Blessing, James V. Fiorica, Bradley J. Monk
International Journal of Gynecological Cancer. 2004-09-01
Press Mentions
- New Concepts Emerging in Treatment of Advanced Ovarian CancerDecember 16th, 2015
- Intraperitoneal Chemotherapy Uptake Sluggish in Ovarian CancerAugust 11th, 2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: